[Expression and Clinical Significance of LINC00475 in Multiple Myeloma].

Objective: To investigate the relative expression level and clinical significance of LINC00475 in serum of patients with multiple myeloma (MM).
Methods: The expression of LINC00475 in serum of 108 MM patients and five MM cell lines including RPMI 8226, NCI-H929, U266, OPM2 and CAG were detected by real-time fluorescence quantitative PCR. The diagnostic value of LINC00475 in MM was evaluated by receiver operating characteristic (ROC) curve analysis. The correlation of LINC00475 with patients' characteristics was analyzed.
Results: Compared with control groups, the expression of LINC00475 was up-regulated in serum of MM patients and MM cell lines (all P < 0.05). ROC curve analysis showed that the optimal cut-off value of LINC00475 was 262.4, the area under curve (AUC) was 0.924(95% CI : 0.884-0.964), and sensitivity and specificity was 83.3% and 91.7%, respectively, which indicated that LINC00475 had good evaluation value in MM patients. Compared with low- LINC00475 expression group, patients in high- LINC00475 expression group had higher levels of β ₂ microglobulin (β ₂ -MG) and Cystatin C (Cys-C) but lower albumin (ALB) (all P < 0.05). Compared with MM patients with International Staging System (ISS) stage I, the expression level of LINC00475 was significantly higher in patients with stage II and III (both P < 0.05).
Conclusion: LINC00475 is helpful to distinguish MM patients from healthy adults, which is correlated with the prognostic indicators such as β ₂ -MG, ALB, and ISS stage.